Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777196 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRALDH1A1CYP3A4HTT | |
| SCHEMBL20764806 | 0.82 | PPARG (0.41) | SMN1; SMN2ALDH1A1CYP3A4HTT | |
| SCHEMBL21176761 | 0.81 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1CYP3A4HTTMEN1 | |
| SCHEMBL5778254 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL304400 | 0.79 | PPARG (0.39) | SMN1; SMN2MAOBALDH1A1CYP3A4HTT | |
| SCHEMBL3686163 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6967717 | 0.73 | TSHR (0.69) | MAOBTSHRMEN1KMT2A | |
| SCHEMBL8484118 | 0.73 | ACHE (0.52) | SMN1; SMN2MAOBTSHRALDH1A1CYP3A4 | |
| SCHEMBL3678445 | 0.72 | TSHR (0.45) | SMN1; SMN2TSHRCYP3A4HTTMEN1 | |
| SCHEMBL4331861 | 0.72 | MAOA (0.42) | SMN1; SMN2MAOBALDH1A1CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380370-A1 | XANTHINE CB1 INHIBITORS | GFB (ABC), LLC | 2022-12-01 | — | — | US | disclosed |
| EP-4034101-A1 | XANTHINE CB1 INHIBITORS | Goldfinch Bio, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380370-A1 | XANTHINE CB1 INHIBITORS | CNR1, GPR119, CNR2 | SMN1; SMN2 2516/4885MAOB 578/4885TSHR 3754/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | SMN1; SMN2 2146/4885MAOB 2351/4885TSHR 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.